Pituitary Cancer Market Covers Global Industry Share, Size by 2023
Author : Vinit Sawant | Published On : 21 May 2021
Growing number of cases getting registered, better financial growth in the market, high integration of various strategies launched by major market players, contribution of researchers, technological advancements, and others are expected to function in dynamic ways to provide the market ample growth opportunities. The high number of geriatric populations getting affected by the disease, high disposable income to avail facilities, better FDA workflow, and others are expected to promote the global market for pituitary cancer.
The global pituitary cancer market is showing growth opportunities at a 9.4% CAGR in the years between 2017 and 2023, which has been defined by Market Research Future (MRFR) as the forecast period. Pituitary cancer can be described as a medical condition that displays an abnormal growth in the pituitary gland. The tumor that happens there starts prohibiting the normal function of the gland and triggers imbalance in the secretion of hormone that causes adverse effects on the body. A large number of growths are benign and can be classed as adenomas.
The global market for pituitary cancer can be segmented by diagnosis, treatment type, and end-user. These segments hold records regarding factors that can promote the market in the coming years.
By diagnosis, the market for pituitary cancer can be segmented into urine test, blood tests, vision testing, brain imaging, and others.
By treatment type, the market for pituitary cancer can be segmented into medications, radiation therapy, surgery, and others. The surgery segment includes endoscopic trans-sphenoidal surgery, craniotomy, and others. The radiation therapy segment comprises, proton beam therapy, external beam radiation, gamma knife stereotactic radiosurgeryand others. The medications segment includes bromocriptine, cabergoline, and others.
By end-user, the market for pituitary cancer can be segmented into clinics, hospitals, research institutes, diagnostic centers, and others.
Eminent players in the global pituitary cancer market are Salzman International (U.S.), Trinity Biotech (Ireland), Sigma-Aldrich Co. LLC (U.S.), Genentech, Inc. (U.S.), Elekta AB (Sweden), Varian Medical Systems, Inc. (U.S.), Ion Beam Applications (Belgium), Accuray Incorporated (U.S.), C. R. Bard, Inc. (U.S.), Nordion, Inc. (Canada), RaySearch Laboratories (Sweden), Isoray Medical, Inc. (U.S.), Mitsubishi Electric Corporation (Japan), Mevion Medical Systems, Inc. (U.S.), and others.